ABSTRACT
To report long-term outcomes of the use of intravitreal bevacizumab in subjects with idiopathic choroidal neovascularization [ICNV]. Six consecutive subjects with ICNV were included in this prospective study. All subjects received 1.25 mg intravitreal bevacizumab at diagnosis. A decrease in best corrected visual acuity [BCVA], presence of increased retinal edema or hemorrhage, increased retinal thickness on optical coherence tomography [OCT] or increased leakage documented by fluorescein angiography prompted further injections of bevacizumab. The study cohort was comprised of 3 males and 3 females with a mean age of 31.17 years. Mean follow-up was 13.8 months [range, 8 months to 20 months]. Following intravitreal bevacizumab injection, vision improved in 3 subjects, remained stable in 3 subjects and no patient lost visual acuity. The mean BCVA improved to logMAR 0.20 at final follow-up from baseline at 0.950 logMAR [P=0.031]. The mean central macular thickness and central foveal thickness at the last postoperative visits were reduced from pre-treatment levels of 374.33 +/- 146.52 and 347.16 +/- 213.97 to 251.20 +/- 35.36 and 215.33 +/- 43.94 ?m, respectively. [P=0.99 and P=0.16, respectively]. Four subjects required repeat treatments. The total number of repeat treatments was 4. Two subjects required no repeat injections, 3 subjects had 1 retreatment and one subject required 2 additional treatments. The injections were well tolerated by all the subjects, with no ocular or systemic adverse events. Intravitreal injection of 1.25 mg bevacizumab in patients with ICNV is effective in improving and stabilizing vision. Additional studies, particularly determination of optimal protocol for timing of re-injection are required to assess long-term effects